Cl.[Cl:2][C:3]1[C:12]2[C:7](=[CH:8][C:9]([O:13][CH2:14][C:15]3[CH:20]=[CH:19][N:18]=[CH:17][CH:16]=3)=[CH:10][CH:11]=2)[N:6]=[CH:5][N:4]=1.[F:21][C:22]1[CH:28]=[C:27]([CH3:29])[C:26]([OH:30])=[CH:25][C:23]=1[NH2:24]>C(O)(C)C>[ClH:2].[F:21][C:22]1[CH:28]=[C:27]([CH3:29])[C:26]([OH:30])=[CH:25][C:23]=1[NH:24][C:3]1[C:12]2[C:7](=[CH:8][C:9]([O:13][CH2:14][C:15]3[CH:20]=[CH:19][N:18]=[CH:17][CH:16]=3)=[CH:10][CH:11]=2)[N:6]=[CH:5][N:4]=1A mixture of 4-chloro-7-(4-pyridylmethoxy)quinazoline hydrochloride (350 mg, 1 mmol) and 2-fluoro-5-hydroxy-4-methylaniline (155 mg, 1.1 mmol), (prepared as described for the starting material in Example 13), in isopropanol (15 ml) was heated at reflux for 1 hour. The resulting precipitate was collected by filtration and purified by reverse phase HPLC using a gradient (0-75%) of methanol in water. Concentrated hydrochloric acid (0.5 ml) was added to the combined fractions of pure product and the solvent was removed by evaporation to give 4-(2-fluoro-5-hydroxy-4-methylanilino)-7-(4-pyridylmethoxy)quinazoline hydrochloride (140 mg, 28%). 1H NMR Spectrum: (DMSOd6) 2.16(s, 3H); 5.69(s, 2H); 6.19(d, 1H); 7.1 (d, 1H); 7.48(d, 1H); 7.66(dd, 1H); 8.06(d, 2H); 8.84(s, 1H); 8.86(d, 1H); 8.90(d, 2H); 9.7(br s, 1H); 11.71(s, 1H) MS-ESI: 377 [MH]+
読み込み中…